Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01152281 · ClinicalTrials.gov registry record · Phase 2
Selective Exposure in HIV Prevention
A Phase 2 study, sponsored by University of Illinois at Urbana-Champaign.
- Completed
- Registry status
- Phase 2
- Development phase
- 722
- Enrollment target
NCT01152281: Completed Phase 2 study, sponsored by University of Illinois at Urbana-Champaign.
NCT01152281 is a Phase 2 study that has completed, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 722 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (443% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01152281, a Phase 2 study, has completed, sponsored by University of Illinois at Urbana-Champaign.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 722 participants
- Enrollment target
Study Summary
Unfortunately, people most at risk for HIV are the least likely to enroll and remain in prevention programs. In our past work, we have learned how to increase enrollment in such programs among this group. We have identified and addressed previously ignored gender-specific and client self-validation issues that conventional interventions often leave not only uncontrolled, but often biased against participation. The present work will extend these methods from enrollment to retention. We intend to recruit a sample of 656 at-risk participants through our collaboration with the Duval County, FL Health Department for our randomized, double-blind trial. Our study will investigate if a meta-intervention video designed for empowering participants as agents of their own change can increase the number of attended sessions relative to a control condition without such a video. This trial will also determine if a meta-intervention video addressing various emotional/social and instrumental benefits of an HIV-prevention-counseling intervention can also increase the number of attended sessions. These two factors will be crossed, and their effects on retention will be estimated for different genders and ethnicities. Effects on clients' attention to the return sessions as reported by the counselor will also be explored among participants who return. We will also conduct mediator analyses for investigating if the meta-intervention has mediating influences on corresponding expectations about the return counseling session. As the inclusion of meta-cognitive measures can alter the efficacy of the intervention, half of the sample will receive measures immediately (0-10 minutes) after exposure to the meta-intervention, before attendance to the next session is registered. The other half will not complete these measures.
Primary Outcome
return rate for 2 upcoming sessions
Interventions
- BEHAVIORAL Maximal Control
- BEHAVIORAL Instrumental and Empowering
- BEHAVIORAL Minimal Control
- BEHAVIORAL Instrumental
- BEHAVIORAL Empowering
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 722 participants |
| Start Date | 2010-05 |
| Est. Completion | 2017-04-30 |
| Phase | Phase 2 |
What the finished NCT01152281 record still lists
NCT01152281 is an interventional study that assigns participants to a tested intervention. The registered 722 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (443% higher).
The record links to 0 conditions, and to 5 interventions - of which Maximal Control is the first listed.
NCT01152281 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01152281 about?
NCT01152281 is a clinical study titled "Selective Exposure in HIV Prevention". Unfortunately, people most at risk for HIV are the least likely to enroll and remain in prevention programs. In our past work, we have learned how to increase enrollment in such programs among this group. We have identified and addressed previously ignored gender-specific and client self-validation ...
What is the current status of trial NCT01152281?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 722 participants. The study started on 2010-05. Estimated completion is 2017-04-30.
What interventions are being tested in trial NCT01152281?
The interventions under investigation include: Maximal Control (BEHAVIORAL), Instrumental and Empowering (BEHAVIORAL), Minimal Control (BEHAVIORAL), Instrumental (BEHAVIORAL), Empowering (BEHAVIORAL).
Who is sponsoring clinical trial NCT01152281?
This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01152281's enrollment target sits among peer trials
722 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06116149 · 722 participants · NA
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- NCT07088068 · 723 participants · Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia